Astellas Pharma (JP:4503) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Astellas Pharma Inc. has received European Commission approval for PADCEV (enfortumab vedotin) in combination with KEYTRUDA (pembrolizumab) as a first-line treatment for advanced urothelial cancer. This marks the first time a treatment has shown superiority over the nearly 40-year standard of platinum-containing chemotherapy, based on the global Phase 3 EV-302 trial’s positive survival results. The new regimen offers a significant improvement in median overall and progression-free survival, heralding a new chapter in the management of this often fatal disease.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.